Altoida, Inc., a trailblazer in AI- and augmented reality (AR)-based digital diagnostics for neurological conditions, has announced the appointment of three globally recognized experts to its Clinical and Scientific Advisory Board. The new members — Dr. Mona Flores, former Global Head of Medical AI at NVIDIA; Dr. Bryan J. Hansen, former Director of Innovative Health, Portfolio Launch Strategy at Johnson & Johnson Innovative Medicine; and Michael Zuendel, founder of Legacy Bridge Private Family Offices and a leading Alzheimer’s advocate — bring unparalleled experience spanning artificial intelligence, pharmaceutical innovation, and patient advocacy.
Their appointments mark a significant milestone for Altoida as the company accelerates the clinical and regulatory advancement of its Digital NeuroMarker Platform, a 10-minute, self-administered, smart device-based tool powered by AR and AI. Designed to detect subtle cognitive changes that precede neurological decline, the platform is positioned to redefine how conditions like Alzheimer’s disease are detected and managed.
A Pivotal Moment in Digital Brain Health
Altoida’s Digital NeuroMarker Platform represents a new frontier in precision neurology. Using everyday smartphone or tablet sensors, the platform evaluates fine motor skills, cognitive performance, and visual-spatial memory through immersive AR-based tasks. The AI system then interprets thousands of digital biomarkers to provide a detailed assessment of brain health.
Unlike traditional paper-based cognitive tests that rely heavily on subjective observation, Altoida’s approach delivers objective, data-driven insights capable of identifying neurodegenerative disease progression years before clinical symptoms appear. The tool is currently undergoing pivotal trials, with the company preparing for FDA submission and eventual global commercialization.
“Altoida is building what will become the new standard for digital brain health assessment,” said Marc Jones, CEO of Altoida. “The addition of Dr. Flores, Dr. Hansen, and Mr. Zuendel enhances our ability to integrate cutting-edge AI, rigorous clinical science, and human-centered design. Their expertise will accelerate our pivotal study, expand our pharma partnerships, and, once FDA-cleared, help bring our platform into clinical use worldwide.”
Jones emphasized that the company’s mission goes beyond diagnostics — it aims to empower early detection, improve treatment development, and enable better patient outcomes across the spectrum of neurological conditions.
Dr. Mona Flores: AI Visionary Bridging Medicine and Machine Learning
Dr. Mona Flores, a pioneer in the use of AI in medicine, joins Altoida’s board after leading NVIDIA’s global medical AI initiatives. At NVIDIA, she was instrumental in advancing AI for healthcare applications, from radiology and pathology to drug discovery and clinical analytics. Her work helped global institutions adopt scalable AI solutions that enhanced patient care and research outcomes.
At Altoida, Dr. Flores will play a central role in guiding the continued evolution of the company’s AI-powered NeuroMarker technology. Her focus will be on advancing model transparency, scalability, and ethical AI deployment in clinical settings.
“Altoida stands at the forefront of applying AI to cognitive diagnostics,” said Dr. Flores. “We are entering an era where responsible AI can transform the way we detect and manage brain diseases. By bringing precision and accessibility to neurological care, Altoida is showing the world how technology and empathy can coexist to change lives.”
Dr. Flores’ appointment underscores Altoida’s commitment to responsible innovation, ensuring that AI-driven healthcare solutions remain explainable, fair, and clinically validated.
Dr. Bryan Hansen: Bridging Neuroscience, Digital Health, and Pharma Innovation
Dr. Bryan J. Hansen, who joins the board from Johnson & Johnson Innovative Medicine, brings extensive expertise at the intersection of neuroscience and digital health. During his tenure at J&J, Dr. Hansen led the Portfolio Launch Strategy for Innovative Health and previously spearheaded data science and digital health strategy across the company’s neurodegeneration pipeline.
He has played a pivotal role in integrating digital biomarkers into clinical development programs and advancing patient-centric trial designs using real-world data and connected devices.
“Altoida’s Digital NeuroMarker Platform bridges rigorous science with practical deployment,” said Dr. Hansen. “By making AI-driven brain health assessments accessible in real-world settings, Altoida is not only enabling earlier diagnosis but also transforming how we develop and evaluate treatments for neurodegenerative diseases.”
Dr. Hansen’s experience in translating scientific discoveries into deployable clinical tools will be critical as Altoida strengthens collaborations with pharmaceutical partners and health systems to bring digital biomarkers into routine use.
Michael Zuendel: The Voice of the Alzheimer’s Patient Community
Michael Zuendel, the third addition to the board, brings a profoundly personal perspective as both a patient advocate and someone living with Alzheimer’s disease. Through his work as the founder of the Initiative to Change the “D-Word”, Zuendel campaigns to shift perceptions around dementia and promote dignity and hope for those affected.
He is also the founder of Legacy Bridge Private Family Offices, where he advises families on philanthropic and health initiatives. His advocacy emphasizes empowerment, early intervention, and patient inclusion in technological innovation.
“A diagnosis should not define a person,” said Zuendel. “By joining Altoida, I hope to help amplify the patient voice and ensure that technology is built with empathy and purpose. Early assessment tools like Altoida’s offer hope — not only for better planning and care but for redefining what it means to live well with Alzheimer’s.”
Zuendel’s appointment highlights Altoida’s dedication to human-centered innovation — ensuring that scientific and technological progress remains grounded in compassion and lived experience.
Building the Future of Precision Neurology
Together, Dr. Flores, Dr. Hansen, and Mr. Zuendel bring a unique convergence of AI expertise, clinical insight, and patient advocacy that strengthens Altoida’s vision for precision neurology. Their addition to the Clinical and Scientific Advisory Board supports the company’s next phase of growth as it prepares for regulatory milestones and market expansion.
Altoida’s NeuroMarker Platform is currently being evaluated in a pivotal multi-site study, designed to validate its accuracy and reproducibility in detecting cognitive decline and differentiating between normal aging and early-stage neurodegenerative conditions. Upon regulatory clearance, the platform is expected to become a cornerstone in clinical trials, primary care, and neurological diagnostics.
“This is a defining moment for digital medicine,” said CEO Marc Jones. “The integration of AI, AR, and patient data will fundamentally change how we understand brain health. Our new advisors will help guide Altoida’s mission to bring these capabilities into everyday clinical practice — at scale, ethically, and globally.”
As the burden of neurological diseases continues to rise, with Alzheimer’s alone affecting over 55 million people worldwide, the need for early and accessible diagnostic tools has never been greater. Altoida’s technology aims to close that gap by providing clinicians, researchers, and patients with a scalable, science-backed, and data-rich platform capable of transforming brain health management.
With the expanded advisory board, Altoida reinforces its position as a category-defining leader in digital brain health — one that combines technological sophistication with deep human understanding to shape the future of neurological care.
